In this video update, HCC CONNECT expert Prof. Matthias Pinter reviews recent real-world data (RWD) discussed in advanced HCC.
He discusses real-world efficacy and safety of systemic therapies, treatment patterns in real-world clinical practice, and RWD on systemic therapy in patient populations excluded from Phase 3 RCT (Child-Pugh class B and with a history of liver transplantation).
Clinical takeaways:
- Although RWD cannot substitute controlled randomised clinical trials, RWD addresses questions not sufficiently answered by clinical trial data
- RWD can provide insights into the performance and outcomes of new anticancer therapies in routine clinical practice, information on patients underrepresented in clinical trials and captures less common and delayed adverse events